<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39459910</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>07</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>The Clinical Effectiveness and Tolerability of Oseltamivir in Unvaccinated Pediatric Influenza Patients during Two Influenza Seasons after the COVID-19 Pandemic: The Impact of Comorbidities on Hospitalization for Influenza in Children.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1576</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v16101576</ELocationID><Abstract><AbstractText>Antiviral therapy such as oseltamivir has been recommended for hospitalized children with suspected and confirmed influenza for almost 20 years. The therapy is officially authorized for newborns two weeks of age or older, however, questions about its safety and effectiveness still surround it. Our goals were to assess the epidemiological features of two consecutive seasonal influenza cases in children following the COVID-19 pandemic; to observe the clinical effectiveness and tolerability of oseltamivir in hospitalized children who were not vaccinated against influenza and had different influenza subtypes, including A(H1N1), A(H3N2), and B; and to identify specific comorbidities associated with influenza in children. We performed an observational study on 1300 children, enrolled between 1 October 2022 and 30 May 2023 and between 1 October 2023 and 4 May 2024, to the IX Pediatric Infectious Diseases Clinical Section of the National Institute of Infectious Diseases "Prof. Dr. Matei Balș". During the 2022-2023 influenza season, 791 pediatric patients tested positive for influenza and received oseltamivir. Of these, 89% (704/791) had influenza A, with 86.4% having subtype A(H1N1) and 13.6% of cases having A(H3N2), and for influenza B, 11% (87/791) of the pediatric patients. Of the total group, 59% were male, and the median age was 2.4 years (1.02-9.28). For the 2023-2024 influenza season, 509 pediatric patients tested positive for influenza, with 56.9% being of the male gender and who were treated with oseltamivir. Of these patients, 81.6% had influenza A and 18.4% had influenza B. Treatment with neuraminidase inhibitors, specifically oseltamivir, 2 mg/kg/dose administered twice daily for 5 days, was well tolerated by the children, and we recorded no deaths. The duration of hospitalization for patients with a fever after the oseltamivir administration was significantly longer for patients with A(H1N1) infection than A(H3N2), during both seasons. We identified more complications in the 2022-2023 season and a decreasing number of influenza B for the 2023-2024 season. Among children with comorbidities, the most common were asthma, gastrointestinal diseases, and metabolic and endocrine diseases. In terms of effectiveness, oseltamivir significantly reduced the intensity of influenza symptoms, thus reducing the number of days of hospitalization (<i>p</i> = 0.001) as well as post-infection complications (<i>p</i> = 0.005) in both groups. In this study, we evaluated the clinical effectiveness of oseltamivir therapy for all influenza types/subtypes in children, and the length of hospitalization. We identified comorbidities associated with the prolonged duration of hospitalization. Influenza vaccination should be the main tool in the prevention of influenza and its complications in children, especially those with comorbidities.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jugulete</LastName><ForeName>Gheorghiță</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-4193-063X</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, University of Medicine and Pharmacy, "Carol Davila", No. 37, Dionisie Lupu Street, 2nd District, 020021 Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>"Matei Balş" National Institute for Infectious Diseases, No. 1, Calistrat Grozovici Street, 2nd District, 021105 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olariu</LastName><ForeName>Mihaela Cristina</ForeName><Initials>MC</Initials><Identifier Source="ORCID">0000-0002-3442-2338</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, University of Medicine and Pharmacy, "Carol Davila", No. 37, Dionisie Lupu Street, 2nd District, 020021 Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>"Matei Balş" National Institute for Infectious Diseases, No. 1, Calistrat Grozovici Street, 2nd District, 021105 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stanescu</LastName><ForeName>Raluca</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Medicine and Pharmacy, "Carol Davila", No. 37, Dionisie Lupu Street, 2nd District, 020021 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luminos</LastName><ForeName>Monica Luminita</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Medicine and Pharmacy, "Carol Davila", No. 37, Dionisie Lupu Street, 2nd District, 020021 Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>"Matei Balş" National Institute for Infectious Diseases, No. 1, Calistrat Grozovici Street, 2nd District, 021105 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pacurar</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-8604-8691</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, University of Medicine and Pharmacy, "Carol Davila", No. 37, Dionisie Lupu Street, 2nd District, 020021 Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, "Grigore Alexandrescu" Emergency Clinical Hospital for Children, No. 30-32, Iancu de Hunedoara Blvd., 011743 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pavelescu</LastName><ForeName>Carmen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Medicine and Pharmacy, "Carol Davila", No. 37, Dionisie Lupu Street, 2nd District, 020021 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Merișescu</LastName><ForeName>Mădălina-Maria</ForeName><Initials>MM</Initials><Identifier Source="ORCID">0009-0000-8902-2051</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, University of Medicine and Pharmacy, "Carol Davila", No. 37, Dionisie Lupu Street, 2nd District, 020021 Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>"Matei Balş" National Institute for Infectious Diseases, No. 1, Calistrat Grozovici Street, 2nd District, 021105 Bucharest, Romania.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>20O93L6F9H</RegistryNumber><NameOfSubstance UI="D053139">Oseltamivir</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053139" MajorTopicYN="Y">Oseltamivir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="Y">Influenza, Human</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="Y">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="Y">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="Y">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053118" MajorTopicYN="Y">Influenza A Virus, H1N1 Subtype</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053122" MajorTopicYN="N">Influenza A Virus, H3N2 Subtype</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012621" MajorTopicYN="N">Seasons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009981" MajorTopicYN="N">Influenza B virus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">children</Keyword><Keyword MajorTopicYN="N">clinical effectiveness</Keyword><Keyword MajorTopicYN="N">comorbidities</Keyword><Keyword MajorTopicYN="N">influenza</Keyword><Keyword MajorTopicYN="N">oseltamivir</Keyword><Keyword MajorTopicYN="N">tolerability</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39459910</ArticleId><ArticleId IdType="pmc">PMC11512198</ArticleId><ArticleId IdType="doi">10.3390/v16101576</ArticleId><ArticleId IdType="pii">v16101576</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nair H., Brooks W.A., Katz M., Roca A., Berkley J.A., Madhi S.A., Simmerman J.M., Gordon A., Sato M., Howie S., et al. Global burden of respiratory infections due to seasonal influenza in young children: A systematic review and meta-analysis. Lancet. 2011;378:1917–1930. doi: 10.1016/S0140-6736(11)61051-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(11)61051-9</ArticleId><ArticleId IdType="pubmed">22078723</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization  . WHO Influenza (Seasonal) Fact Sheet. World Health Organization; Geneva, Switzerland: 2023.  [(accessed on 24 July 2024)].  sheets/detail/influenza-seasonal. Available online:  https://www.who.int/publications/m/item/influenza-update-n--485. sheets/detail/influenza-seasonal.</Citation></Reference><Reference><Citation>Wei C.J., Crank M.C., Shiver J., Graham B.S., Mascola J.R., Nabel G.J. Next generation influenza vaccines: Opportunities and challenges. Nat. Rev. Drug Discov. 2020;19:239–252. doi: 10.1038/s41573-019-0056-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-019-0056-x</ArticleId><ArticleId IdType="pmc">PMC7223957</ArticleId><ArticleId IdType="pubmed">32060419</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsen S.J., Winn A.K., Budd A.P., Prill M.M., Steel J., Midgley C.M., Kniss K., Burns E., Rowe T., Foust A., et al. Changes in Influenza and Other Respiratory Virus Activity During the COVID-19 Pandemic—United States, 2020–2021. MMWR Morb. Mortal. Wkly. Rep. 2021;70:1013–1019. doi: 10.15585/mmwr.mm7029a1.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7029a1</ArticleId><ArticleId IdType="pmc">PMC8297694</ArticleId><ArticleId IdType="pubmed">34292924</ArticleId></ArticleIdList></Reference><Reference><Citation>Blyth C.C., Richmond P.C., Jacoby P., Thornton P., Regan A., Robins C., Kelly H., Smith D.W., Effler P.V. The impact of pandemic A (H1N1) pdm09 influenza and vaccine-associated adverse events on parental attitudes and influenza vaccine uptake in young children. Vaccine. 2014;32:4075–4081. doi: 10.1016/j.vaccine.2014.05.055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2014.05.055</ArticleId><ArticleId IdType="pubmed">24877764</ArticleId></ArticleIdList></Reference><Reference><Citation>Centrul National de Supraveghere si Control al Bolilor Transmisibile  COVID-19 Raport Săptămânal de Supraveghere, Date. Raportate Până la Data 14 May 2023.  [(accessed on 1 March 2024)].  Available online:  https://www.cnscbt.ro/index.php/informari-saptamanale/gripa/3464-informare-infectii-respiratorii-08-05-2023-14-05-2023-s-19/file.</Citation></Reference><Reference><Citation>Miron V.D., Draganescu A.C., Sandulescu O., Visan C.A., Merisescu M.M., Cercel A.S., Pitigoi D., Rafila A., Mihaela O., Dorobatg J., et al. Pneumococcal colonization and pneumococcal disease in children with influenza: Clinical, laboratory, and epidemiological features. Rev. Chim. 2018;69:2749–2753. doi: 10.37358/RC.18.10.6618.</Citation><ArticleIdList><ArticleId IdType="doi">10.37358/RC.18.10.6618</ArticleId></ArticleIdList></Reference><Reference><Citation>European Centre for Disease Prevention and Control (ECDC)   Seasonal Influenza Vaccines. ECDC; Stockholm, Sweden:  [(accessed on 18 August 2023)].  Available online:  https://www.ecdc.europa.eu/en/seasonal-influenza/prevention-and-control/seasonal-influenza-vaccines.</Citation></Reference><Reference><Citation>Chow E.J., Doyle J.D., Uyeki T.M. Influenza virus-related critical illness: Prevention, diagnosis, treatment. Crit. Care. 2019;23:214. doi: 10.1186/s13054-019-2491-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-019-2491-9</ArticleId><ArticleId IdType="pmc">PMC6563376</ArticleId><ArticleId IdType="pubmed">31189475</ArticleId></ArticleIdList></Reference><Reference><Citation>Principi N., Esposito S. Severe influenza in children: Incidence and risk factors. Expert Rev. Anti-Infect. Ther. 2016;14:961–968. doi: 10.1080/14787210.2016.1227701.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14787210.2016.1227701</ArticleId><ArticleId IdType="pubmed">27560100</ArticleId></ArticleIdList></Reference><Reference><Citation>Pneumonia Etiology Research for Child Health (PERCH) Study Group Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: The PERCH multi-country case-control study. Lancet. 2019;394:757–779. doi: 10.1016/S0140-6736(19)30721-4. Erratum in Lancet 2019, 394, 736.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(19)30721-4</ArticleId><ArticleId IdType="pmc">PMC6727070</ArticleId><ArticleId IdType="pubmed">31257127</ArticleId></ArticleIdList></Reference><Reference><Citation>Jefferson T., Jones M., Doshi P., Spencer E.A., Onakpoya I., Heneghan C.J. Oseltamivir for influenza in adults and children: Systematic review of clinical study reports and summary of regulatory comments. BMJ. 2014;348:g2545. doi: 10.1136/bmj.g2545.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.g2545</ArticleId><ArticleId IdType="pmc">PMC3981975</ArticleId><ArticleId IdType="pubmed">24811411</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization (WHO)   Recommended Composition of Influenza Virus Vaccines for Use in the 2022–2023 Northern Hemisphere Influenza Season. WHO; Geneva, Switzerland: 2022.  [(accessed on 4 February 2024)].  Available online:  https://www.who.int/publications/m/item/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2022-2023-northern-hemisphere-influenza-season.</Citation></Reference><Reference><Citation>Dobson J., Whitley R.J., Pocock S., Monto A.S. Oseltamivir treatment for influenza in adults: A meta-analysis of randomised controlled trials. Lancet. 2015;385:1729–1737. doi: 10.1016/S0140-6736(14)62449-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(14)62449-1</ArticleId><ArticleId IdType="pubmed">25640810</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkatesan S., Myles P.R., Bolton K.J., Muthuri S.G., Al Khuwaitir T., Anovadiya A.P., Azziz-Baumgartner E., Bajjou T., Bassetti M., Beovic B., et al. Neuraminidase Inhibitors and Hospital Length of Stay: A Meta-analysis of Individual Participant Data to Determine Treatment Effectiveness Among Patients Hospitalized With Nonfatal 2009 Pandemic Influenza A(H1N1) Virus Infection. J. Infect. Dis. 2020;221:356–366. doi: 10.1093/infdis/jiz152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiz152</ArticleId><ArticleId IdType="pmc">PMC7313925</ArticleId><ArticleId IdType="pubmed">31314899</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding Q., Lu P., Fan Y., Xia Y., Liu M. The clinical characteristics of pneumonia patients coinfected with 2019 novel coronavirus and influenza virus in Wuhan, China. J. Med. Virol. 2020;92:1549–1555. doi: 10.1002/jmv.25781.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25781</ArticleId><ArticleId IdType="pmc">PMC7228290</ArticleId><ArticleId IdType="pubmed">32196707</ArticleId></ArticleIdList></Reference><Reference><Citation>Merișescu M.-M., Luminos M.L., Pavelescu C., Jugulete G. Clinical Features and Outcomes of the Association of Co-Infections in Children with Laboratory-Confirmed Influenza during the 2022–2023 Season: A Romanian Perspective. Viruses. 2023;15:2035. doi: 10.3390/v15102035.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15102035</ArticleId><ArticleId IdType="pmc">PMC10611070</ArticleId><ArticleId IdType="pubmed">37896811</ArticleId></ArticleIdList></Reference><Reference><Citation>Dominguez-Cherit G., Lapinsky S.E., Macias A.E., Pinto R., Espinosa-Perez L., de la Torre A., Poblano-Morales M., Baltazar-Torres J.A., Bautista E., Martinez A., et al. Critically Ill patients with 2009 influenza A(H1N1) in Mexico. JAMA. 2009;302:1880–1887. doi: 10.1001/jama.2009.1536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2009.1536</ArticleId><ArticleId IdType="pubmed">19822626</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar A., Zarychanski R., Pinto R., Cook D.J., Marshall J., Lacroix J., Stelfox T., Bagshaw S., Choong K., Lamontagne F., et al. Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA. 2009;302:1872–1879. doi: 10.1001/jama.2009.1496.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2009.1496</ArticleId><ArticleId IdType="pubmed">19822627</ArticleId></ArticleIdList></Reference><Reference><Citation>Sellers S.A., Hagan R.S., Hayden F.G., Fischer W.A., 2nd The hidden burden of influenza: A review of the extra-pulmonary complications of influenza infection. Influenza Other Respir. Viruses. 2017;11:372–393. doi: 10.1111/irv.12470.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/irv.12470</ArticleId><ArticleId IdType="pmc">PMC5596521</ArticleId><ArticleId IdType="pubmed">28745014</ArticleId></ArticleIdList></Reference><Reference><Citation>Groves H.E., Papenburg J., Mehta K., Bettinger J.A., Sadarangani M., Halperin S.A., Morris S.K., Bancej C., Burton C., Embree J., et al. The effect of the COVID-19 pandemic on influenza-related hospitalization, intensive care admission and mortality in children in Canada: A population-based study. Lancet Reg. Health Am. 2022;7:100132. doi: 10.1016/j.lana.2021.100132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lana.2021.100132</ArticleId><ArticleId IdType="pmc">PMC8913102</ArticleId><ArticleId IdType="pubmed">35291567</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratre Y.K., Vishvakarma N.K., Bhaskar L.V.K.S., Verma H.K. Dynamic Propagation and Impact of Pandemic Influenza A (2009 H1N1) in Children: A Detailed Review. Curr. Microbiol. 2020;77:3809–3820. doi: 10.1007/s00284-020-02213-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00284-020-02213-x</ArticleId><ArticleId IdType="pmc">PMC7505219</ArticleId><ArticleId IdType="pubmed">32959089</ArticleId></ArticleIdList></Reference><Reference><Citation>Short K.R., Kasper J., van der Aa S., Andeweg A.C., Zaaraoui-Boutahar F., Goeijenbier M., Richard M., Herold S., Becker C., Scott D.P., et al. Influenza virus damages the alveolar barrier by disrupting epithelial cell tight junctions. Eur. Respir. J. 2016;47:954–966. doi: 10.1183/13993003.01282-2015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.01282-2015</ArticleId><ArticleId IdType="pubmed">26743480</ArticleId></ArticleIdList></Reference><Reference><Citation>Mondal P., Sinharoy A., Gope S. The influence of COVID-19 on influenza and respiratory syncytial virus activities. Infect. Dis. Rep. 2022;14:134–141. doi: 10.3390/idr14010017.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/idr14010017</ArticleId><ArticleId IdType="pmc">PMC8872472</ArticleId><ArticleId IdType="pubmed">35200444</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Q.S., Wood T., Jelley L., Jennings T., Jefferies S., Daniells K., Nesdale A., Dowell T., Turner N., Campbell-Stokes P., et al. Impact of the COVID-19 nonpharmaceutical interventions on influenza and other respiratory viral infections in New Zealand. Nat. Commun. 2021;12:1001. doi: 10.1038/s41467-021-21157-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-21157-9</ArticleId><ArticleId IdType="pmc">PMC7881137</ArticleId><ArticleId IdType="pubmed">33579926</ArticleId></ArticleIdList></Reference><Reference><Citation>Funk A.L., Florin T.A., Kuppermann N., Tancredi D.J., Xie J., Kim K., Neuman M.I., Ambroggio L., Plint A.C., Mintegi S., et al. Outcomes of SARS-CoV-2–Positive Youths Tested in Emergency Departments: The Global PERN-COVID-19 Study. JAMA Netw. Open. 2022;5:e2142322. doi: 10.1001/jamanetworkopen.2021.42322.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.42322</ArticleId><ArticleId IdType="pmc">PMC8753506</ArticleId><ArticleId IdType="pubmed">35015063</ArticleId></ArticleIdList></Reference><Reference><Citation>Minodier L., Charrel R.N., Ceccaldi P.E., van der Werf S., Blanchon T., Hanslik T., Falchi A. Prevalence of gastrointestinal symptoms in patients with influenza, clinical significance, and pathophysiology of human influenza viruses in faecal samples: What do we know? Virol. J. 2015;12:215. doi: 10.1186/s12985-015-0448-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-015-0448-4</ArticleId><ArticleId IdType="pmc">PMC4676820</ArticleId><ArticleId IdType="pubmed">26651485</ArticleId></ArticleIdList></Reference><Reference><Citation>Jugulete G., Merisescu M.M., Bastian A.E., Zurac S., Stoicescu S.M., Luminos M.L. Severe form of A1H1 influenza in a child—Case presentation. Rom. J. Leg. Med. 2019;26:387–391.</Citation></Reference><Reference><Citation>National Institute of Public Health (NIPH)  National Centre for Surveillance and Control of Communicable Diseases.  [(accessed on 28 April 2023)]; Available online:  https://cnsisp.insp.gov.ro/</Citation></Reference><Reference><Citation>Willis G.A., Preen D.B., Richmond P.C., Jacoby P., Effler P.V., Smith D.W., Robins C., Borland M.L., Levy A., Keil A.D., et al. The impact of influenza infection on young children, their family and the health care system. Influenza Other Respir Viruses. 2019;13:18–27. doi: 10.1111/irv.12604.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/irv.12604</ArticleId><ArticleId IdType="pmc">PMC6304317</ArticleId><ArticleId IdType="pubmed">30137663</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamidani S., Garg S., Rolfes M.A., Campbell A.P., Cummings C.N., Haston J.C., Openo K.P., Fawcett E., Chai S.J., Herlihy R., et al. Epidemiology, clinical characteristics, and outcomes of influenza-associated hospitalizations in U.S. children over 9 seasons following the 2009 H1N1 pandemic. Clin. Infect. Dis. 2022;75:1930–1939. doi: 10.1093/cid/ciac296.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac296</ArticleId><ArticleId IdType="pubmed">35438769</ArticleId></ArticleIdList></Reference><Reference><Citation>Jugulete G., Luminos M., Pavelescu C., Merișescu M.M. Remdesivir Efficacy and Tolerability in Children with COVID-19-Associated Allergic Comorbidities such as Asthma, Allergic Rhinitis, and Atopic Dermatitis. Children. 2023;10:810. doi: 10.3390/children10050810.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/children10050810</ArticleId><ArticleId IdType="pmc">PMC10217479</ArticleId><ArticleId IdType="pubmed">37238359</ArticleId></ArticleIdList></Reference><Reference><Citation>de Boer G., Braunstahl G.-J., Hendriks R., Tramper-Stranders G. Asthma exacerbation prevalence during the COVID-19 lockdown in a moderate-severe asthma cohort. BMJ Open Respir. Res. 2021;8:e000758. doi: 10.1136/bmjresp-2020-000758.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjresp-2020-000758</ArticleId><ArticleId IdType="pmc">PMC8102860</ArticleId><ArticleId IdType="pubmed">33952584</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzpatrick T., McNally J.D., Stukel T.A., Lu H., Fisman D., Kwong J.C., Guttmann A. Family and child risk factors for early-life RSV illness. Pediatrics. 2021;147:e2020029090. doi: 10.1542/peds.2020-029090.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2020-029090</ArticleId><ArticleId IdType="pubmed">33737374</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris D.E., Cleary D.W., Clarke S.C. Secondary bacterial infections associated with influenza pandemics. Front. Microbiol. 2017;8:1041. doi: 10.3389/fmicb.2017.01041.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2017.01041</ArticleId><ArticleId IdType="pmc">PMC5481322</ArticleId><ArticleId IdType="pubmed">28690590</ArticleId></ArticleIdList></Reference><Reference><Citation>Gawronski O., Briassoulis G., El Ghannudi Z., Ilia S., Sánchez-Martín M., Chiusolo F., Jensen C.S., Manning J.C., Valla F.V., Pavelescu C., et al. European survey on Paediatric Early Warning Systems, and other processes used to aid the recognition and response to children’s deterioration on hospital wards. Nurs. Crit. Care. 20242024 doi: 10.1111/nicc.13096. early view .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nicc.13096</ArticleId><ArticleId IdType="pubmed">38867428</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalil A.C., Thomas P.G. Influenza virus-related critical illness: Pathophysiology and epidemiology. Crit. Care. 2019;23:258. doi: 10.1186/s13054-019-2539-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-019-2539-x</ArticleId><ArticleId IdType="pmc">PMC6642581</ArticleId><ArticleId IdType="pubmed">31324202</ArticleId></ArticleIdList></Reference><Reference><Citation>Joseph C., Togawa Y., Shindo N. Bacterial and viral infections associated with influenza. Influenza Other Respir Viruses. 2013;7:105–113. doi: 10.1111/irv.12089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/irv.12089</ArticleId><ArticleId IdType="pmc">PMC5909385</ArticleId><ArticleId IdType="pubmed">24034494</ArticleId></ArticleIdList></Reference><Reference><Citation>Vardakas K.Z., Theocharis G., Tansarli G.S., Rafailidis P., Falagas M.E. Impact of oseltamivir use on the reduction of complications in patients with influenza: A prospective study. Arch. Virol. 2016;161:2511–2518. doi: 10.1007/s00705-016-2941-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-016-2941-5</ArticleId><ArticleId IdType="pubmed">27368992</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugaya N., Mitamura K., Yamazaki M., Tamura D., Ichikawa M., Kimura K., Kawakami C., Kiso M., Ito M., Hatakeyama S., et al. Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children. Clin. Infect. Dis. 2007;44:197–202. doi: 10.1086/509925.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/509925</ArticleId><ArticleId IdType="pubmed">17173216</ArticleId></ArticleIdList></Reference><Reference><Citation>Spinelli A., Buoncristiano M., Kovacs V.A., Yngve A., Spiroski I., Obreja G. Prevalence of severe obesity among primary school children in 21 European countries. Obes Facts. 2019;12:244–258. doi: 10.1159/000500436.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000500436</ArticleId><ArticleId IdType="pmc">PMC6547273</ArticleId><ArticleId IdType="pubmed">31030201</ArticleId></ArticleIdList></Reference><Reference><Citation>Longmore D.K., Miller J.E., Bekkering S., Saner C., Mifsud E., Zhu Y., Saffery R., Nichol A., Colditz G., Short K.R., et al. Diabetes and Overweight/Obesity Are Independent, Nonadditive Risk Factors for In-Hospital Severity of COVID-19: An International, Multicenter Retrospective Meta-analysis. Diabetes Care. 2021;44:1281–1290. doi: 10.2337/dc20-2676.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc20-2676</ArticleId><ArticleId IdType="pmc">PMC8247499</ArticleId><ArticleId IdType="pubmed">33858854</ArticleId></ArticleIdList></Reference><Reference><Citation>Malosh R.E., Martin E.T., Heikkinen T., Brooks W.A., Whitley R.J., Monto A.S. Efficacy and Safety of Oseltamivir in Children: Systematic Review and Individual Patient Data Meta-analysis of Randomized Controlled Trials. Clin. Infect. Dis. 2018;66:1492–1500. doi: 10.1093/cid/cix1040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/cix1040</ArticleId><ArticleId IdType="pubmed">29186364</ArticleId></ArticleIdList></Reference><Reference><Citation>Uyeki T.M. Oseltamivir Treatment of Influenza in Children. Clin. Infect. Dis. 2018;66:1501–1503. doi: 10.1093/cid/cix1150.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/cix1150</ArticleId><ArticleId IdType="pmc">PMC6669028</ArticleId><ArticleId IdType="pubmed">29315362</ArticleId></ArticleIdList></Reference><Reference><Citation>Mylonakis S.C., Mylona E.K., Kalligeros M., Shehadeh F., Chan P.A., Mylonakis E. How Comorbidities Affect Hospitalization from Influenza in the Pediatric Population. Int. J. Environ. Res. Public Health. 2022;19:2811. doi: 10.3390/ijerph19052811.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph19052811</ArticleId><ArticleId IdType="pmc">PMC8910429</ArticleId><ArticleId IdType="pubmed">35270503</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>